

Brompton Global Healthcare Income & Growth ETF
Summary of Investment Portfolio as at September 30, 2021

Total Net Asset Value \$ 68,564,482

Portfolio Composition	% of Net Asset Value
Europe	
Denmark	
Pharmaceuticals	4.2%
Germany	
Pharmaceuticals	3.8%
Great Britain	
Pharmaceuticals	1.4%
Ireland	
Healthcare Equipment	7.1%
Switzerland	
Healthcare Equipment	4.0%
Total Europe	20.5%
North America	
United States	
Healthcare Equipment	24.0%
Life Sciences Tools and Services	21.1%
Pharmaceuticals	12.2%
Healthcare Supplies	5.8%
Healthcare Facilities	4.0%
Managed Healthcare	3.6%
Healthcare Services	3.2%
Biotechnology	2.9%
Healthcare Technology	2.7%
Total North America	79.5%
Cash and short-term investments	0.6%
Other net liabilities	(0.6%)
Total Net Asset Value	100.0%

Top 25 Holdings	% of Net Asset Value
Agilent Technologies Inc	5.0%
IDEXX Laboratories Inc	4.9%
Danaher Corp	4.4%
Novo Nordisk A/S	4.2%
Intuitive Surgical Inc	4.2%
Straumann Holding AG	4.0%
Thermo Fisher Scientific Inc	4.0%
HCA Healthcare Inc	4.0%
Zoetis Inc	3.9%
Edwards Lifesciences Corp	3.9%
West Pharmaceutical Services Inc	3.8%
Merck KGaA	3.8%
IQVIA Holdings Inc	3.8%
Steris plc	3.7%
UnitedHealth Group Inc	3.6%
Medtronic PLC	3.4%
Abbott Laboratories	3.4%
Johnson & Johnson	3.4%
Laboratory Corporation of America Holdings	3.2%
Stryker Corp	3.2%
Eli Lilly and Co	3.1%
Charles River Laboratories International Inc	3.0%
Abbvie Inc	2.9%
Mettler-Toledo International Inc	2.8%
Veeva Systems Inc	2.7%
Total	92.3%

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available within 60 days of each quarter end.